Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 30, 2026, 3:58 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1201–1224 of 5,204 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Thoracic Neoplasm Clear all
Recruiting Phase 1 Interventional

Study of RMC-5127 in Patients With Advanced KRAS G12V-Mutant Solid Tumors

NCT07349537
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC), Colorectal Cancer (CRC), Pancreatic Adenocarcinoma, Pancreatic Ductal Adenocarcinoma (PDAC), PDAC, CRC, NSCLC, Pancreatic Cancer, Lung Cancer (NSCLC), Advanced Solid Tumors
Interventions
RMC-5127, daraxonrasib, cetuximab
Drug
Lead sponsor
Revolution Medicines, Inc.
Industry
Eligibility
18 Years and older
Enrollment
574 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2028
U.S. locations
9
States / cities
New Haven, Connecticut • Baltimore, Maryland • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Sep 17, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

GE Healthcare VolumeRAD Lung Nodule Detection Study

NCT00963651
View directory record Official record
Conditions
Pulmonary Nodule, Solitary, Multiple Pulmonary Nodules
Interventions
Chest tomosynthesis and X-ray
Device
Lead sponsor
American College of Radiology - Image Metrix
Industry
Eligibility
18 Years and older
Enrollment
187 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009 – 2013
U.S. locations
3
States / cities
Ann Arbor, Michigan • Durham, North Carolina • Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 24, 2013 · Synced Oct 30, 2026, 3:58 PM EDT
Active, not recruiting Phase 2 Interventional

A Study of Cemiplimab Plus Chemotherapy Versus Cemiplimab Plus Chemotherapy Plus Other Cancer Treatments for Adult Patients With Operable Non-Small Cell Lung Cancer (NSCLC)

NCT06465329
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Cemiplimab, Platinum-based chemotherapy, REGN7075
Drug
Lead sponsor
Regeneron Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
120 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2030
U.S. locations
12
States / cities
Orange, California • Skokie, Illinois • Detroit, Michigan + 8 more
Source: ClinicalTrials.gov public record
Updated Aug 24, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Recruiting Not applicable Interventional

Continuous Positive Airway Pressure Device or Deep Inspiration Breath Hold in Reducing Tumor Motion in Patients Undergoing Stereotactic Body Radiation Therapy for Lung Cancer

NCT03422302
View directory record Official record
Conditions
Lung Carcinoma, Malignant Respiratory Tract Neoplasm, Metastatic Malignant Neoplasm in the Lung
Interventions
Biphasic Positive Airway Pressure, Computed Tomography, Continuous Positive Airway Pressure, Deep Inspiration Breath Hold, Radiation Therapy Treatment Planning and Simulation, Stereotactic Body Radiation Therapy
Device · Procedure · Radiation
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2028
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Aug 11, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Recruiting Phase 3 Interventional

A Study to Assess Intravenous ABBV-1480 Combined With Chemotherapy Versus Pembrolizumab Combined With Chemotherapy for the First Line Treatment of Locally Advanced/Metastatic Non-Small Cell Lung Cancer in Adult Participants

NCT07756645
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
ABBV-1480, Pembrolizumab, Carboplatin, Paclitaxel, Nab- Paclitaxel
Drug
Lead sponsor
AbbVie
Industry
Eligibility
18 Years and older
Enrollment
940 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2029
U.S. locations
1
States / cities
Fort Wayne, Indiana
Source: ClinicalTrials.gov public record
Updated Oct 20, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Active, not recruiting Phase 3 Interventional

A Global Study to Assess the Effects of Durvalumab + Domvanalimab Following Concurrent Chemoradiation in Participants With Stage III Unresectable NSCLC

NCT05211895
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Durvalumab, Domvanalimab, Placebo
Drug · Other
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
791 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
32
States / cities
Chandler, Arizona • Phoenix, Arizona • Fountain Valley, California + 28 more
Source: ClinicalTrials.gov public record
Updated Aug 28, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Terminated Phase 2 Interventional

Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer

NCT00850577
View directory record Official record
Conditions
Non-small Cell Lung Cancer (NSCLC)
Interventions
Paclitaxel, Carboplatin, CT-322, Bevacizumab, Bevacizumab placebo (ie saline solution)
Drug
Lead sponsor
Bristol-Myers Squibb
Industry
Eligibility
18 Years and older
Enrollment
255 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2013
U.S. locations
20
States / cities
Tucson, Arizona • San Diego, California • Orlando, Florida + 17 more
Source: ClinicalTrials.gov public record
Updated Oct 12, 2015 · Synced Oct 30, 2026, 3:58 PM EDT
Completed Phase 2 Interventional

Randomized Study Of CP-675,206 or Best Supportive Care Immediately After Platinum-Based Therapy For Non-Small Cell Lung Cancer (NSCLC)

NCT00312975
View directory record Official record
Conditions
Carcinoma, Non-small-cell Lung
Interventions
CP-675,206, best supportive care
Drug
Lead sponsor
AstraZeneca
Industry
Eligibility
18 Years and older
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2010
U.S. locations
14
States / cities
Bentonville, Arkansas • Fayetteville, Arkansas • Orange, California + 10 more
Source: ClinicalTrials.gov public record
Updated Jun 7, 2012 · Synced Oct 30, 2026, 3:58 PM EDT
Completed Phase 2 Interventional

Pemetrexed Disodium Plus Gemcitabine in Treating Patients With Locally Advanced or Metastatic Non-Small Cell Lung Cancer

NCT00022646
View directory record Official record
Conditions
Lung Cancer
Interventions
gemcitabine hydrochloride, pemetrexed disodium
Drug
Lead sponsor
Alliance for Clinical Trials in Oncology
Other
Eligibility
18 Years and older
Enrollment
157 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2001 – 2008
U.S. locations
22
States / cities
Scottsdale, Arizona • Jacksonville, Florida • Peoria, Illinois + 19 more
Source: ClinicalTrials.gov public record
Updated Dec 7, 2016 · Synced Oct 30, 2026, 3:58 PM EDT
Not listed Phase 1Phase 2 Interventional

Rhenium Re 188 P2045 in Patients With Lung Cancer Who Have Received or Refused to Receive Prior Chemotherapy

NCT00100256
View directory record Official record
Conditions
Lung Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Small Cell, Neoplasm Recurrence, Local
Interventions
Rhenium (Re 188 P2045, BAY86-5284)
Drug
Lead sponsor
Andarix Pharmaceuticals
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2025
U.S. locations
2
States / cities
Iowa City, Iowa • Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated Nov 7, 2022 · Synced Oct 30, 2026, 3:58 PM EDT
Terminated Phase 2 Interventional

RONICICLIB / Placebo in Combination With Chemotherapy in Small Cell Lung Cancer

NCT02161419
View directory record Official record
Conditions
Small Cell Lung Carcinoma
Interventions
Roniciclib (BAY1000394), Placebo
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
142 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2016
U.S. locations
7
States / cities
Boca Raton, Florida • Port Saint Lucie, Florida • St Louis, Missouri + 4 more
Source: ClinicalTrials.gov public record
Updated Jun 25, 2018 · Synced Oct 30, 2026, 3:58 PM EDT
Completed Phase 2 Interventional

A Study to Test the Effect of the Drug Larotrectinib in Adults and Children With NTRK-fusion Positive Solid Tumors

NCT02576431
View directory record Official record
Conditions
Solid Tumors Harboring NTRK Fusion
Interventions
BAY2757556 (Larotrectinib, Vitrakvi)
Drug
Lead sponsor
Bayer
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2025
U.S. locations
18
States / cities
Palo Alto, California • Santa Monica, California • Pembroke Pines, Florida + 13 more
Source: ClinicalTrials.gov public record
Updated Jul 1, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Not yet recruiting Not applicable Interventional Accepts healthy volunteers

Home-Based Respiratory Muscle Training and Aerobic Exercise Programs to Improve Lung Health in Current and Former Cigarette Smokers

NCT07553819
View directory record Official record
Conditions
Lung Carcinoma
Interventions
Accelerometry, Aerobic Exercise, Biospecimen Collection, Educational Intervention, Electronic Health Record Review, Physical Performance Testing, Respiratory Muscle Training, Supportive Care, Survey Administration
Procedure · Other
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
50 Years and older
Enrollment
200 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2026 – 2029
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated Aug 21, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Recruiting No phase listed Observational

Clinical Utility of Management of Patients With Pulmonary Nodules Using the Percepta Nasal Swab Classifier

NCT06426628
View directory record Official record
Conditions
Pulmonary Nodule, Solitary, Lung Cancer
Interventions
Not listed
Lead sponsor
Veracyte, Inc.
Industry
Eligibility
29 Years to 85 Years
Enrollment
2,400 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2027
U.S. locations
22
States / cities
Hartford, Connecticut • Stamford, Connecticut • Bay Pines, Florida + 19 more
Source: ClinicalTrials.gov public record
Updated Nov 13, 2024 · Synced Oct 30, 2026, 3:58 PM EDT
Active, not recruiting Not applicable Interventional

A Pilot Study of Single Fraction Stereotactic Body Radiation Therapy (SBRT) in Central Non-Small Cell Lung Cancer

NCT05138900
View directory record Official record
Conditions
Non Small Cell Lung Cancer
Interventions
SBRT
Radiation
Lead sponsor
Roswell Park Cancer Institute
Other
Eligibility
18 Years and older
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
1
States / cities
Buffalo, New York
Source: ClinicalTrials.gov public record
Updated May 5, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Recruiting Phase 1 Interventional

Study of XB010 in Subjects With Solid Tumors

NCT06545331
View directory record Official record
Conditions
Locally Advanced or Metastatic Solid Tumors, Esophageal Squamous Cell Cancer, Head and Neck Squamous Cell Cancer, NSCLC (Non-small Cell Lung Cancer), Hormone-receptor-positive Breast Cancer, Triple Negative Breast Cancer (TNBC)
Interventions
XB010, Pembrolizumab
Drug
Lead sponsor
Exelixis
Industry
Eligibility
18 Years and older
Enrollment
396 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
16
States / cities
Irvine, California • Los Angeles, California • Washington D.C., District of Columbia + 12 more
Source: ClinicalTrials.gov public record
Updated Oct 30, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Recruiting Not applicable Interventional

Lung Cancer Screening of Family Members of Patients With Mutation-Driven Lung Cancer

NCT07062172
View directory record Official record
Conditions
Lung Cancer, Driver Mutation
Interventions
Low Dose CT Scan
Diagnostic Test
Lead sponsor
University of California, Irvine
Other
Eligibility
18 Years to 80 Years
Enrollment
1,753 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2028
U.S. locations
1
States / cities
Orange, California
Source: ClinicalTrials.gov public record
Updated Jul 14, 2025 · Synced Oct 30, 2026, 3:58 PM EDT
Completed No phase listed Observational

Thoracic OncoGeriatric Assessment (TOGA) Trials

NCT00591981
View directory record Official record
Conditions
Thoracic Neoplasms, Lung Neoplasms, Esophagus Neoplasms, Pleural Neoplasms, Thymus Neoplasms
Interventions
TOGA Tools
Behavioral
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
70 Years and older
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Jun 5, 2023 · Synced Oct 30, 2026, 3:58 PM EDT
Completed No phase listed Observational

Frailty Index and Geriatric Assessment in Predicting Toxicity to Front-Line Chemotherapy in Treating Patients With Stage IV Non-Small Cell Lung Cancer

NCT01026467
View directory record Official record
Conditions
Recurrent Non-small Cell Lung Cancer, Stage IV Non-small Cell Lung Cancer
Interventions
cisplatin, carboplatin, questionnaire administration
Drug · Other
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
Not listed
Enrollment
45 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
2
States / cities
Syracuse, New York • Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Jul 5, 2018 · Synced Oct 30, 2026, 3:58 PM EDT
Active, not recruiting Phase 2 Interventional

Ipilimumab and Nivolumab in Recurrent Extensive Stage Small Cell Lung Cancer After Receiving Platinum-based Chemotherapy

NCT03670056
View directory record Official record
Conditions
Small Cell Lung Cancer
Interventions
Combination immunotherapy with Ipilimumab and Nivolumab
Drug
Lead sponsor
Yale University
Other
Eligibility
18 Years and older
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2025
U.S. locations
1
States / cities
New Haven, Connecticut
Source: ClinicalTrials.gov public record
Updated Jul 20, 2025 · Synced Oct 30, 2026, 3:58 PM EDT
Recruiting Phase 2 Interventional

Local Consolidative Therapy and Durvalumab for Oligoprogressive and Polyprogressive Stage III NSCLC After Chemoradiation and Anti-PD-L1 Therapy

NCT04892953
View directory record Official record
Conditions
Stage III Lung Cancer AJCC v8, Stage III Lung Non-Small Cell Cancer AJCC v7, Stage IIIA Lung Cancer AJCC v8, Stage IIIA Lung Non-Small Cell Cancer AJCC v7, Stage IIIB Lung Cancer AJCC v8, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IIIC Lung Cancer AJCC v8
Interventions
Carboplatin, Durvalumab, Gemcitabine, Local Consolidation Therapy, Nab-paclitaxel, Paclitaxel, Pemetrexed, Quality-of-Life Assessment, Questionnaire Administration
Drug · Biological · Procedure + 1 more
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2029
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Sep 3, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Recruiting Phase 1Phase 2 Interventional

Neoadjuvant Dupilumab and Cemiplimab in Patients With Early-stage Resectable NSCLC

NCT06088771
View directory record Official record
Conditions
Non-Small Cell Lung Cancer
Interventions
Dupilumab, Cemiplimab
Biological
Lead sponsor
Icahn School of Medicine at Mount Sinai
Other
Eligibility
18 Years and older
Enrollment
21 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2027
U.S. locations
1
States / cities
New York, New York
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Completed Not applicable Interventional Results available

Comparing Smoking Cessation Interventions Among Underserved Patients Referred for Lung Cancer Screening

NCT04798664
View directory record Official record
Conditions
Smoking Cessation
Interventions
Removal of Financial Barriers, Financial Incentives, Mobile Health Application
Behavioral
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
3,228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2025
U.S. locations
5
States / cities
Oakland, California • Detroit, Michigan • Danville, Pennsylvania + 2 more
Source: ClinicalTrials.gov public record
Updated Feb 25, 2026 · Synced Oct 30, 2026, 3:58 PM EDT
Completed Phase 2 Interventional

Dose Range Study of Anamorelin in Patients With Non-small Cell Lung Cancer

NCT00622193
View directory record Official record
Conditions
Carcinoma, Non-Small-Cell Lung
Interventions
anamorelin HCl, placebo
Drug
Lead sponsor
Helsinn Therapeutics (U.S.), Inc
Industry
Eligibility
18 Years to 85 Years
Enrollment
228 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2009
U.S. locations
19
States / cities
Little Rock, Arkansas • Melbourne, Florida • Augusta, Georgia + 12 more
Source: ClinicalTrials.gov public record
Updated Apr 14, 2017 · Synced Oct 30, 2026, 3:58 PM EDT